United States - English - NLM (National Library of Medicine)

guangzhou qiao anni cosmetics co., ltd. - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - wipe directly, the action time for hands is not more than 2 minutes, and the action time for intact skin and mmucous membranes is not more than 5 minutes disinfection sterilization no rinseing

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - desvenlafaxine (unii: ng99554anw) (desvenlafaxine - unii:ng99554anw) - desvenlafaxine 50 mg - desvenlafaxine is indicated for the treatment of adults with major depressive disorder (mdd) [see clinical studies (14)] . - hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the desvenlafaxine extended-release tablets formulation.  angioedema has been reported in patients treated with desvenlafaxine [see adverse reactions (6.1)] . - the use of maois intended to treat psychiatric disorders with desvenlafaxine or within 7 days of stopping treatment with desvenlafaxine is contraindicated because of an increased risk of serotonin syndrome. the use of desvenlafaxine within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.7) and warnings and precautions (5.2)]. - starting desvenlafaxine in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration (2.8) and

United States - English - NLM (National Library of Medicine)

macoven pharmaceuticals - desvenlafaxine (unii: ng99554anw) (desvenlafaxine - unii:ng99554anw) - desvenlafaxine 50 mg - desvenlafaxine extended-release tablets are indicated for the treatment of adults with major depressive disorder (mdd) [see clinical studies (14)] . - hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the desvenlafaxine extended-release tablets formulation.  angioedema has been reported in patients treated with desvenlafaxine [see adverse reactions (6.1)] . - the use of maois intended to treat psychiatric disorders with desvenlafaxine extended-release tablets or within 7 days of stopping treatment with desvenlafaxine extended-release tablets is contraindicated because of an increased risk of serotonin syndrome. the use of desvenlafaxine extended-release tablets within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration  (2.8)   and  warnings and precautions  (5.2)]. -   starting desvenlafaxine extended-release tablets in a patient who is being treated with maois such as linezolid or intraveno

United States - English - NLM (National Library of Medicine)

pernix therapeutics - desvenlafaxine (unii: ng99554anw) (desvenlafaxine - unii:ng99554anw) - desvenlafaxine 50 mg - khedezla is indicated for the treatment of adults with major depressive disorder (mdd) [see clinical studies (14)] . - hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the khedezla extended-release tablets formulation.  angioedema has been reported in patients treated with desvenlafaxine [see adverse reactions (6.1)] . - the use of maois intended to treat psychiatric disorders with khedezla or within 7 days of stopping treatment with khedezla is contraindicated because of an increased risk of serotonin syndrome. the use of khedezla within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration  (2.8)   and  warnings and precautions  (5.2)]. -   starting khedezla in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see dosage and administration (2.8) and warnings and precautions (5.

United States - English - NLM (National Library of Medicine)

cvs pharmacy, inc. - dibucaine (unii: l6jw2tjg99) (dibucaine - unii:l6jw2tjg99) - dibucaine 10 mg in 1 g - use temporarily relives pain and itching due to hemorrhoids or other anorectal disorders do not use - in or near the eyes - in children under 2 years of age stop use and ask a doctor if - bleeding occurs - condition worsens or does not improve within 7 days directions - adults and children 12 years and over: if possible, clean the affected area with mild soap and warm water and rinse thoroughly. gently dry by patting or blotting with toilet tissue or a soft cloth before applying - apply externally to the affected area up to 3 or 4 times daily - children under 12 years of age: ask a doctor

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories inc. - dibucaine (unii: l6jw2tjg99) (dibucaine - unii:l6jw2tjg99) - dibucaine 1 g in 100 g - hemorrhoidal ointment - temporarily relieves pain and itching due to hemorrhoids or other anorectal disorders

United States - English - NLM (National Library of Medicine)

attix pharmaceuticals inc - etidronate disodium (unii: m16pxg993g) (etidronate disodium - unii:m16pxg993g) - etidronate disodium 1 kg in 1 kg

United States - English - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - dibucaine (unii: l6jw2tjg99) (dibucaine - unii:l6jw2tjg99) - dibucaine 1 g in 100 g - topical anesthetic uses: - for temporary relief of pain and itching associated with: - sunburn - minor burns - hemorrhoids - cuts - scratches - insect bites - stings

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - desvenlafaxine (unii: ng99554anw) (desvenlafaxine - unii:ng99554anw) - desvenlafaxine extended-release tablets are indicated for the treatment of adults with major depressive disorder (mdd) [see clinical studies (14)] . - hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the desvenlafaxine extended-release tablets formulation. angioedema has been reported in patients treated with desvenlafaxine extended-release tablets [see adverse reactions (6.1)]. - the use of maois intended to treat psychiatric disorders with desvenlafaxine extended-release tablets or within 7 days of stopping treatment with desvenlafaxine extended-release tablets are contraindicated because of an increased risk of serotonin syndrome. the use of desvenlafaxine extended-release tablets within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.7) and warnings and precautions (5.2)]. - starting desvenlafaxine extended-release tablets in a patient who is being treated with maois such as linez

United States - English - NLM (National Library of Medicine)

cvs pharmacy - dibucaine (unii: l6jw2tjg99) (dibucaine - unii:l6jw2tjg99) -